Bifogade filer
Induct - Interim Report Q2 2025
Kurs
-1,04%
Kurs
-1,04%
Open
3,90
High
4,02
Low
3,62
Close
3,80
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
2,10 MNOK
Likviditet
2,10 MNOK
Rel. mcap
1,98%
Antal aktier
559 625
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2026-06-12 | N/A | Årsstämma |
| 2026-02-12 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-13 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-14 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-13 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2025-06-12 | - | Årsstämma |
| 2025-04-10 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-17 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2024-06-14 | - | Årsstämma |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | Årsstämma |
| 2023-06-15 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-15 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-02 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2022-02-15 | - | Bokslutskommuniké 2021 |
| 2021-11-01 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-27 | - | Extra Bolagsstämma 2021 |
| 2021-08-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-28 | - | Årsstämma |
| 2021-05-04 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2021-05-03 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-16 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-29 | - | Årsstämma |
| 2020-04-30 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-04 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2020-02-03 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-05 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2019-04-30 | - | Kvartalsrapport 2019-Q1 |
| 2018-12-20 | - | Extra Bolagsstämma 2018 |
| 2018-04-13 | - | X-dag ordinarie utdelning INDCT 0.00 NOK |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-15 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-09-30 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | - | Bokslutskommuniké 2015 |
| 2016-04-18 | - | Extra Bolagsstämma 2016 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Informationsteknik |
| Industri | Programvara |
2025-08-14 07:00:00
The Interim report for Q2 2025 for Induct AS has been approved by the Board of
Directors.
- EBITDA decreased to NOK 3,35 in Q2 2025 from NOK 3,73 million in Q2 2024 but
increased by NOK 0,35 million compared to Q1 2025.
- Total operating costs increased to NOK 1,2 million in Q2 2025 from NOK 1,18
million in Q2 2024.
- Our partnership and collaboration discussions AstraZeneca and Portsmouth are
progressing very well and there is a joint intention to expand the Severe Asthma
module across England, but also the UK.
- Direct dialogue between Induct and AstraZeneca to assess other partnership
opportunities.
- Continued focus on increasing revenues to strengthen our EBITDA further and
deliver solid financial results.
- Goal to expand our technology and provide digital clinical pathways to other
diseases, including diabetes and cardiovascular diseases, to name a few, each of
which has the same, or larger, global revenue potential than severe asthma.